Learn from people with more than 10 years of experience

PRESS RELEASE: clinical study for our lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV), completes recruitment!

Edwin Swart
81 (updated: 06-11-2022 13:18)
gedea-press-release-02112052568.jpg
10-02-2022 11:46

"Really fantastic feeling to have finalized enrolment of the 150 patients in our placebo-controlled study in bacterial vaginosis #Nefertiti - What an achievement by the Gedea Biotech AB team, the sites, LINK Medical Research, Link2Trials - and what a milestone for us!" 

Read the full press release on the Gedea Biotech AB website: Link

PRESS RELEASE: clinical study for our lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV), completes recruitment!

The randomized double-blind placebo-controlled study is designed to confirm the safety and efficacy of pHyph and is coordinated by  across 6 UK and 4 Swedish sites. Results from the first treatment period (day 0-7) are expected in Q2 and for the follow-up period in Q3. This would put us in a strong position to achieve #CEmarking by the end of the year.

 

Like or Share

link2trials

Tell us more. Solutions from Link2Trials go one step further. Let us know your goals

Thank you we will contact you soon
An error occurred. Please try again

Link2Trials

  • 1223 HL Hilversum
  • The Netherlands
  • Chamber of Commerce: 32122355

Privacy statement

beamer
eu
imi
efpia